Taurine

Taurine earns 9.0/10 for cardiovascular because Guan 2020 reports Confirmed meta-analysis on obesity, BP, and lipid outcomes; supports cardiometabolic breadth. Tzang 2024 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Taurine matters for this use case. The practical move is to define one cardiovascular marker before starting, then judge Taurine by that marker instead of by mechanism alone. Taurine is most defensible when the target is specific and the user is willing to stop if the signal is absent.

The metabolic health case for Taurine is 8.0/10 because Tzang 2024 reports 25 RCTs and 1024 participants; lower SBP, DBP, fasting blood glucose, and triglycerides; no significant adverse-effect excess. Guan 2020 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Taurine matters for this use case. The practical move is to define one metabolic health marker before starting, then judge Taurine by that marker instead of by mechanism alone. Taurine is most defensible when the target is specific and the user is willing to stop if the signal is absent.

For sleep quality, Taurine scores 8.5/10 because Jia 2008 reports Mechanistic receptor paper supporting GABA-A activity relevant to sleep and calmness claims. The score stays conditional because Taurine still needs better outcome data for this exact use case. The practical move is to define one sleep quality marker before starting, then judge Taurine by that marker instead of by mechanism alone. Taurine is most defensible when the target is specific and the user is willing to stop if the signal is absent.

Mechanistically, Taurine fits mitochondrial at 8.0/10 because Tzang 2024 reports 25 RCTs and 1024 participants; lower SBP, DBP, fasting blood glucose, and triglycerides; no significant adverse-effect excess. Tzang 2024 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Taurine matters for this use case. The practical move is to define one mitochondrial marker before starting, then judge Taurine by that marker instead of by mechanism alone. Taurine is most defensible when the target is specific and the user is willing to stop if the signal is absent.

The strongest longevity argument for Taurine is 7.8/10 because Singh 2023 reports Flagship aging paper; taurine declines with age and supplementation improved lifespan or healthspan markers in non-human models. The score stays conditional because Taurine still needs better outcome data for this exact use case. The practical move is to define one longevity marker before starting, then judge Taurine by that marker instead of by mechanism alone. Taurine is most defensible when the target is specific and the user is willing to stop if the signal is absent.

Taurine is a 7.5/10 endurance and cardio fit because Waldron 2018 reports 10 peer-reviewed articles; isolated oral taurine showed a small positive endurance-performance signal. Tzang 2024 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Taurine matters for this use case. The practical move is to define one endurance and cardio marker before starting, then judge Taurine by that marker instead of by mechanism alone. Taurine is most defensible when the target is specific and the user is willing to stop if the signal is absent.

Taurine looks most relevant to blood-sugar control at 7.5/10 because Tzang 2024 reports 25 RCTs and 1024 participants; lower SBP, DBP, fasting blood glucose, and triglycerides; no significant adverse-effect excess. Systematic 2022 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Taurine matters for this use case. The practical move is to define one blood-sugar control marker before starting, then judge Taurine by that marker instead of by mechanism alone. Taurine is most defensible when the target is specific and the user is willing to stop if the signal is absent.

Evidence for Taurine in inflammation control lands at 7.0/10 because Ahmadian 2017 reports Heart-failure RCT; 500 mg three times daily for 2 weeks affected atherogenic and inflammatory markers. The score stays conditional because Taurine still needs better outcome data for this exact use case. The practical move is to define one inflammation control marker before starting, then judge Taurine by that marker instead of by mechanism alone. Taurine is most defensible when the target is specific and the user is willing to stop if the signal is absent.

The practical neuroprotection read on Taurine is 7.0/10 because Wu 2010 reports Corrected v0.x identifier; CNS mechanism review covering osmoregulation, calcium homeostasis, and neuroprotection. Jia 2008 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Taurine matters for this use case. The practical move is to define one neuroprotection marker before starting, then judge Taurine by that marker instead of by mechanism alone. Taurine is most defensible when the target is specific and the user is willing to stop if the signal is absent.

For users targeting liver support, Taurine earns 6.8/10 because Tzang 2024 reports 25 RCTs and 1024 participants; lower SBP, DBP, fasting blood glucose, and triglycerides; no significant adverse-effect excess. Tzang 2024 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Taurine matters for this use case. The practical move is to define one liver support marker before starting, then judge Taurine by that marker instead of by mechanism alone. Taurine is most defensible when the target is specific and the user is willing to stop if the signal is absent.

Taurine looks most relevant to strength and power at 6.5/10 because Tzang 2024 reports 25 RCTs and 1024 participants; lower SBP, DBP, fasting blood glucose, and triglycerides; no significant adverse-effect excess. Tzang 2024 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Taurine matters for this use case. The practical move is to define one strength and power marker before starting, then judge Taurine by that marker instead of by mechanism alone. Taurine is most defensible when the target is specific and the user is willing to stop if the signal is absent.

Taurine earns 6.5/10 for cognition and focus because Tzang 2024 reports 25 RCTs and 1024 participants; lower SBP, DBP, fasting blood glucose, and triglycerides; no significant adverse-effect excess. Tzang 2024 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Taurine matters for this use case. The practical move is to define one cognition and focus marker before starting, then judge Taurine by that marker instead of by mechanism alone. Taurine is most defensible when the target is specific and the user is willing to stop if the signal is absent.

For antioxidant, Taurine scores 6.5/10 because Tzang 2024 reports 25 RCTs and 1024 participants; lower SBP, DBP, fasting blood glucose, and triglycerides; no significant adverse-effect excess. Tzang 2024 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Taurine matters for this use case. The practical move is to define one antioxidant marker before starting, then judge Taurine by that marker instead of by mechanism alone. Taurine is most defensible when the target is specific and the user is willing to stop if the signal is absent.

For recovery and repair, Taurine scores 6.3/10 because Waldron 2018 reports 10 peer-reviewed articles; isolated oral taurine showed a small positive endurance-performance signal. Ahmadian 2017 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Taurine matters for this use case. The practical move is to define one recovery and repair marker before starting, then judge Taurine by that marker instead of by mechanism alone. Taurine is most defensible when the target is specific and the user is willing to stop if the signal is absent.

The anxiety case for Taurine is 6.0/10 because Zhang 2007 reports Mechanistic in vivo anxiety model supporting glycine receptor pathway. The score stays conditional because Taurine still needs better outcome data for this exact use case. The practical move is to define one anxiety marker before starting, then judge Taurine by that marker instead of by mechanism alone. Taurine is most defensible when the target is specific and the user is willing to stop if the signal is absent.

Mechanistically, Taurine fits eye and vision support at 6.0/10 because Tzang 2024 reports 25 RCTs and 1024 participants; lower SBP, DBP, fasting blood glucose, and triglycerides; no significant adverse-effect excess. Tzang 2024 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Taurine matters for this use case. The practical move is to define one eye and vision support marker before starting, then judge Taurine by that marker instead of by mechanism alone. Taurine is most defensible when the target is specific and the user is willing to stop if the signal is absent.

The strongest body composition argument for Taurine is 5.5/10 because Sasidharan 2026 reports 220 randomized; no significant overall fatigue benefit, with only hypothesis-generating post hoc subgroup signal. The score stays conditional because Taurine still needs better outcome data for this exact use case. The practical move is to define one body composition marker before starting, then judge Taurine by that marker instead of by mechanism alone. Taurine is most defensible when the target is specific and the user is willing to stop if the signal is absent.

Taurine is a 5.5/10 immune function fit because Tzang 2024 reports 25 RCTs and 1024 participants; lower SBP, DBP, fasting blood glucose, and triglycerides; no significant adverse-effect excess. Tzang 2024 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Taurine matters for this use case. The practical move is to define one immune function marker before starting, then judge Taurine by that marker instead of by mechanism alone. Taurine is most defensible when the target is specific and the user is willing to stop if the signal is absent.

Taurine earns 5.5/10 for HRV and vagal tone because Tzang 2024 reports 25 RCTs and 1024 participants; lower SBP, DBP, fasting blood glucose, and triglycerides; no significant adverse-effect excess. Tzang 2024 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Taurine matters for this use case. The practical move is to define one HRV and vagal tone marker before starting, then judge Taurine by that marker instead of by mechanism alone. Taurine is most defensible when the target is specific and the user is willing to stop if the signal is absent.

Evidence for Taurine in bone and joint support lands at 5.3/10 because Tzang 2024 reports 25 RCTs and 1024 participants; lower SBP, DBP, fasting blood glucose, and triglycerides; no significant adverse-effect excess. Tzang 2024 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Taurine matters for this use case. The practical move is to define one bone and joint support marker before starting, then judge Taurine by that marker instead of by mechanism alone. Taurine is most defensible when the target is specific and the user is willing to stop if the signal is absent.

The practical mood read on Taurine is 5.0/10 because Zhang 2007 reports Mechanistic in vivo anxiety model supporting glycine receptor pathway. The score stays conditional because Taurine still needs better outcome data for this exact use case. The practical move is to define one mood marker before starting, then judge Taurine by that marker instead of by mechanism alone. Taurine is most defensible when the target is specific and the user is willing to stop if the signal is absent.

For users targeting male fertility, Taurine earns 5.0/10 because Tzang 2024 reports 25 RCTs and 1024 participants; lower SBP, DBP, fasting blood glucose, and triglycerides; no significant adverse-effect excess. Tzang 2024 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Taurine matters for this use case. The practical move is to define one male fertility marker before starting, then judge Taurine by that marker instead of by mechanism alone. Taurine is most defensible when the target is specific and the user is willing to stop if the signal is absent.